Physician profile
Jennifer Wright
NPI 1679992341
$9,327.76
in general payments reported to CMS, 2019-2025
36 companies · $2,875 in 2025
The $2,875 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,595 · 2022: $1,871 · 2023: $1,565 · 2024: $1,422 · 2025: $2,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,425 · Consulting Fee: $250 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,424.82 |
| Consulting Fee | $250.00 |
| Education | $187.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,471.95 | 2021-2025 | |
| Pfizer INC. | $798.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $713.14 | 2022-2025 | Sotyktu |
| Incyte Corporation | $671.98 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $509.49 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $487.04 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $481.13 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Arcutis Biotherapeutics, INC. | $470.65 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $461.90 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $406.57 | 2023-2025 | Bimzelx |
| Lilly USA, LLC | $332.75 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $329.06 | 2021-2025 | |
| Amgen INC. | $300.16 | 2021-2025 | Otezla, Otezla |
| Medimetriks Pharmaceuticals, INC. | $250.00 | 2025 | Neo-Synalar |
| Botanix Sb INC | $202.83 | 2025 | Sofdra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $169.28 | 2021-2025 | Adbry |
| Almirall LLC | $157.74 | 2021-2022 | |
| Galderma Laboratories, L.P. | $152.36 | 2021-2025 | |
| Organon LLC | $134.75 | 2024-2025 | Vtama |
| Gilead Sciences, INC. | $103.17 | 2024 | |
| Revance Therapeutics, INC. | $100.95 | 2025 | Daxxify |
| Mayne Pharma Commercial LLC | $82.45 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $71.60 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.02 | 2021-2023 | Siliq, Targretin |
| Allergan, INC. | $66.69 | 2021-2022 | |
| Dermavant Sciences, INC. | $47.26 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.36 | 2023-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $42.77 | 2021 | |
| Verrica Pharmaceuticals INC. | $33.97 | 2024-2025 | Ycanth |
| Journey Medical Corporation | $33.75 | 2022 | |
| Organogenesis INC. | $28.47 | 2024 | |
| Strata Skin Sciences, INC. | $24.69 | 2025 | Xtrac |
| Hill Dermaceuticals, INC. | $22.74 | 2025 | Tolak |
| Merck Sharp & Dohme LLC | $20.56 | 2023 | Keytruda |
| Epi Health, LLC | $19.64 | 2022 | |
| Kyowa Kirin, INC. | $16.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.